ArticleMedical science monitor : international medical journal of experimental and clinical research2017
Prognostic Value of Plasma Long Noncoding RNA ANRIL for In-Stent Restenosis.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 29 citations in OpenAlex.
- Prognostic Factors for In-stent Restenosis After Cerebrovascular Stent Implantation among Ischemic Stroke Patients.Current neurovascular research · 2026Article
- Deciphering the enigma: long noncoding RNAs in disease pathogenesis and therapeutic prospects.Molecular and cellular biochemistry · 2025Review
- Long noncoding RNAs in familial hypercholesterolemia: biomarkers, therapeutics, and AI in precision medicine.Lipids in health and disease · 2025Review
- ANRIL, H19 and TUG1: a review about critical long non-coding RNAs in cardiovascular diseases.Molecular biology reports · 2023Review
- Noncoding RNAs in Vascular Cell Biology and Restenosis.Biology · 2022Review
- Diabetes and restenosis.Cardiovascular diabetology · 2022Review
- Expression ratio of circular to linear ANRIL in hypertensive patients with coronary artery disease.Scientific reports · 2022Article
- Predictive value of using plasma long non-coding RNAs ANRIL and HOXA11-AS for in-stent restenosis.Experimental and therapeutic medicine · 2022Article
- The Role of ANRIL in Atherosclerosis.Disease markers · 2022Review
- Role of long non-coding RNAs in adipogenesis: State of the art and implications in obesity and obesity-associated diseases.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2021Review
- Serum NT-proBNP and TUG1 as novel biomarkers for elderly hypertensive patients with heart failure with preserved ejection fraction.Experimental and therapeutic medicine · 2021Article
- Long non-coding RNA cyclin-dependent kinase inhibitor 2B antisense ribonucleic acid 1 is associated with in-stent restenosis and promotes human carotid artery smooth muscle cell proliferation and migration by sponging miR-143-3p.Experimental and therapeutic medicine · 2021Article
- Non-Coding RNAs as Blood-Based Biomarkers in Cardiovascular Disease.International journal of molecular sciences · 2020Review
- A Roadmap for Fixing the Heart: RNA Regulatory Networks in Cardiac Disease.Molecular therapy. Nucleic acids · 2020Review
- LncRNA ANRIL/miR-125a axis exhibits potential as a biomarker for disease exacerbation, severity, and inflammation in bronchial asthma.Journal of clinical laboratory analysis · 2020Article
- The roles of long noncoding RNAs in myocardial pathophysiology.Bioscience reports · 2019Review
- Endothelial function and dysfunction in the cardiovascular system: the long non-coding road.Cardiovascular research · 2019Review
- Long Non-coding RNAs: At the Heart of Cardiac Dysfunction?Frontiers in physiology · 2019Review
- Circulating Long Noncoding RNA LIPCAR Acts as a Novel Biomarker in Patients with ST-Segment Elevation Myocardial Infarction.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND In-stent restenosis (ISR) remains a major cause of failure of contemporary percutaneous revascularization therapies. Invasive biomarkers to improve the prognosis of ISR should be considered. This study aimed to investigate the association between plasma ANRIL expression and ISR. MATERIAL AND METHODS A total of 444 patients were included in this research. Serial coronary angiography was performed at baseline (before and after intervention) and within 36 months' follow-up. ISR was defined as >50% diameter stenosis at follow-up. ANRIL expression was quantified using reverse transcription-PCR. An area under the ROC curve (auROC) was generated to assess the diagnostic values of ANRIL. Logistic regression models were used to assess the independent risk factors for ISR. RESULTS Plasma ANRIL expression was significantly increased in patients with ISR, as compared with that in patients without ISR (1.6 [1.1-2.5] vs. 0.9 [0.6-1.3], P<0.001). The auROC (95% confidence interval [CI]) of plasma ANRIL in diagnosing ISR was 0.745 (0.687-0.811). Multiple logistic regression models indicated that drinking (odds ratio [OR]=2.09, 95% CI: 1.08-4.04, P=0.028), hypertension (OR=2.01, 95% CI: 1.14-3.57, P=0.017), diabetes (OR=3.15, 95% CI: 1.63-3.57, P<0.001), low-density lipoprotein (OR=3.14, 95% CI: 1.57-6.31, P=0.001), and ANRIL (OR=2.21, 95% CI: 1.68-2.92, P<0.001) were the independent risk factors for ISR. CONCLUSIONS We found that higher ANRIL expression is associated with ISR, indicating that ANRIL may be an optimal prognostic factor for ISR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.